Hybrid Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffolds in Combination With Drug-Eluting Stents or Drug-Coated Balloons for Complex Coronary Lesions

Palmerini, 2015, Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis, J Am Coll Cardiol, 65, 2496, 10.1016/j.jacc.2015.04.017

Otsuka, 2014, Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans, Circulation, 129, 211, 10.1161/CIRCULATIONAHA.113.001790

Kereiakes, 2016, Bioresorbable vascular scaffolds for coronary revascularization, Circulation, 134, 168, 10.1161/CIRCULATIONAHA.116.021539

Onuma, 2011, Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?, Circulation, 123, 779, 10.1161/CIRCULATIONAHA.110.971606

Tanaka, 2015, Positive vessel remodeling and appearance of pulsatile wall motion at long-term follow-up after bioresorbable scaffold implantation in a chronic total occlusion, J Am Coll Cardiol Intv, 8, 1635, 10.1016/j.jcin.2015.06.022

Onuma, 2016, Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial, EuroIntervention, 12, 1090, 10.4244/EIJY16M09_01

Chevalier, 2016, Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial, EuroIntervention, 12, 1102, 10.4244/EIJY16M08_01

Ellis, 2015, Everolimus-eluting bioresorbable scaffolds for coronary artery disease, N Engl J Med, 373, 1905, 10.1056/NEJMoa1509038

Gao, 2015, Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China trial, J Am Coll Cardiol, 66, 2298, 10.1016/j.jacc.2015.09.054

Stone, 2016, 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis, Lancet, 387, 1277, 10.1016/S0140-6736(15)01039-9

Lipinski, 2016, Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: a systematic review and meta-analysis, J Am Coll Cardiol Intv, 9, 12, 10.1016/j.jcin.2015.09.024

Capodanno, 2014, Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry, EuroIntervention, 10, 1144, 10.4244/EIJY14M07_11

Tanaka, 2017, Clinical outcomes of a real world cohort following bioresorbable vascular scaffold implantation utilizing an optimized implantation strategy, EuroIntervention, 12, 1730, 10.4244/EIJ-D-16-00247

Ormiston, 2015, An independent bench comparison of two bioresorbable drug-eluting coronary scaffolds (Absorb and DESolve) with a durable metallic drug-eluting stent (ML8/Xpedition), EuroIntervention, 11, 60, 10.4244/EIJY15M02_03

Foin, 2016, Bioabsorbable vascular scaffold overexpansion: insights from in vitro post-expansion experiments, EuroIntervention, 11, 1389, 10.4244/EIJY15M07_02

Colombo, 2016, Who is thrombogenic: the scaffold or the doctor? Back to the future!, J Am Coll Cardiol Intv, 9, 25, 10.1016/j.jcin.2015.09.021

Tanaka, 2016, Bioresorbable scaffolds: what does “less forgiving” mean?, J Am Coll Cardiol Intv, 9, 1856, 10.1016/j.jcin.2016.06.040

Robaei, 2016, “Full bioresorbable jacket”: alternative to very long segment metallic stenting in a young patient with diffuse coronary artery disease, Int J Cardiol, 223, 361, 10.1016/j.ijcard.2016.08.179

Kleber, 2013, Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group, Clin Res Cardiol, 102, 785, 10.1007/s00392-013-0609-7

Kawamoto, 2016, The bioresorbable scaffold: will oversizing affect outcomes?, J Am Coll Cardiol Intv, 9, 299, 10.1016/j.jcin.2015.11.019

Tanaka, 2016, Case illustration of the difference between bench test and in-vivo scaffold fracture thresholds, Int J Cardiol, 225, 20, 10.1016/j.ijcard.2016.09.097

Tanaka, 2016, Bioresorbable vascular scaffolds: from patient selection to optimal scaffold implantation; tips and tricks to minimize device failure, Catheter Cardiovasc Interv, 88, 10, 10.1002/ccd.26812

Serruys, 2016, Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial, Lancet, 388, 2479, 10.1016/S0140-6736(16)32050-5

Raber, 2015, Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings, J Am Coll Cardiol, 66, 1901, 10.1016/j.jacc.2015.08.853

Karanasos, 2015, Angiographic and optical coherence tomography insights into bioresorbable scaffold thrombosis: single-center experience, Circ Cardiovasc Interv, 8, e002369, 10.1161/CIRCINTERVENTIONS.114.002369

Kawamoto, 2016, Contained coronary rupture following bioresorbable scaffold implantation in a small vessel, Int J Cardiol, 209, 24, 10.1016/j.ijcard.2016.02.026

Kolandaivelu, 2011, Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings, Circulation, 123, 1400, 10.1161/CIRCULATIONAHA.110.003210

Ishibashi, 2015, Relation between bioresorbable scaffold sizing using QCA-Dmax and clinical outcomes at 1 year in 1,232 patients from 3 study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II), J Am Coll Cardiol Intv, 8, 1715, 10.1016/j.jcin.2015.07.026

Moussa, 2001, Characteristics of patients with a large discrepancy in coronary artery diameter between quantitative angiography and intravascular ultrasound, Am J Cardiol, 88, 294, 10.1016/S0002-9149(01)01644-7

Latib, 2015, 3-year follow-up of the Balloon Elution and Late Loss Optimization study (BELLO), J Am Coll Cardiol Intv, 8, 1132, 10.1016/j.jcin.2015.04.008

Naganuma, 2014, No more metallic cages: an attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel, Int J Cardiol, 172, 618, 10.1016/j.ijcard.2014.01.081

Ielasi, 2016, Hybrid strategy with a bioresorbable scaffold and a drug-coated balloon for diffuse coronary artery disease: the “no more metallic cages” multicentre pilot experience, EuroIntervention, 11, e1589, 10.4244/EIJV11I14A309

Kawamoto, 2016, Bioresorbable scaffolds for the management of coronary bifurcation lesions, J Am Coll Cardiol Intv, 9, 989, 10.1016/j.jcin.2016.02.038

Gori, 2016, Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry, EuroIntervention, 12, e550, 10.4244/EIJY15M09_10

Puricel, 2016, Bioresorbable coronary scaffold thrombosis: multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors, J Am Coll Cardiol, 67, 921, 10.1016/j.jacc.2015.12.019

Kawamoto, 2016, OCT Images of Longitudinal Deformation Following BVS Implantation in the Right Coronary Ostium, J Am Coll Cardiol Img, 9, 751, 10.1016/j.jcmg.2015.04.013

Basavarajaiah, 2014, Can bioabsorbable scaffolds be used in calcified lesions?, Catheter Cardiovasc Interv, 84, 48, 10.1002/ccd.24939

Miyazaki, 2016, The use of a scoring balloon for optimal lesion preparation prior to bioresorbable scaffold implantation: a comparison with conventional balloon predilatation, EuroIntervention, 11, e1580, 10.4244/EIJV11I14A308

Tanaka, 2016, Clinical outcomes following bifurcation double-stenting with bioresorbable scaffolds, Catheter Cardiovasc Interv, 88, 854, 10.1002/ccd.26579

Tanaka, 2016, Preliminary report of clinical outcomes after single crossover bioresorbable scaffold implantation without routine side branch strut dilation, Catheter Cardiovasc Interv, 88, 865, 10.1002/ccd.26586

Kawamoto, 2015, Clinical outcomes following bioresorbable scaffold implantation for bifurcation lesions: overall outcomes and comparison between provisional and planned double stenting strategy, Catheter Cardiovasc Interv, 86, 644, 10.1002/ccd.26045

Naganuma, 2017, Bioresorbable vascular scaffold use for coronary bifurcation lesions: a substudy from GHOST EU registry, Catheter Cardiovasc Interv, 89, 47, 10.1002/ccd.26634

Colombo, 2009, Randomized study of the crush technique versus provisional side-branch stenting in true coronary bifurcations: the CACTUS (Coronary Bifurcations: Application of the Crushing Technique Using Sirolimus-Eluting Stents) study, Circulation, 119, 71, 10.1161/CIRCULATIONAHA.108.808402

Dzavik, 2014, The absorb bioresorbable vascular scaffold in coronary bifurcations: insights from bench testing, J Am Coll Cardiol Intv, 7, 81, 10.1016/j.jcin.2013.07.013

Jamshidi, 2016, A novel approach to treat in-stent restenosis: 6- and 12-month results using the everolimus-eluting bioresorbable vascular scaffold, EuroIntervention, 11, 1479, 10.4244/EIJV11I13A287

Moscarella, 2016, Long-term clinical outcomes after bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: a multicenter Italian experience, Circ Cardiovasc Interv, 9, e003148, 10.1161/CIRCINTERVENTIONS.115.003148

Tanaka, 2016, Bioresorbable scaffold failure for recurrent restenosis at multi-layered stent fracture, Int J Cardiol, 214, 360, 10.1016/j.ijcard.2016.03.207

D'Ascenzo, 2015, Radial strength and expansion of scaffold struts remain a concern when considering a PCI with bioresorbable vascular scaffold, Int J Cardiol, 191, 254, 10.1016/j.ijcard.2015.04.148